Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non‐small‐cell lung cancer-Reference-Cited by-同舟云学术

Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non‐small‐cell lung cancer

Published:2020-08-06 Issue:2 Volume:17 Page:
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Icht Oded¹^ORCID,Domachevsky Liran²,Groshar David²,Dudnik Elizabeth¹,Rotem Ofer¹,Allen Aaron M.¹,Peled Nir³,Reinhorn Daniel¹,Jacobi Oded¹,Shochat Tzippy⁴,Bernstine Hanna²,Zer Alona¹

Affiliation:

1. Thoracic Cancer Unit Davidoff Cancer Institute Rabin Medical Center Petah Tikva affiliated to the Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

2. Department of Nuclear Medicine Rabin Medical Center Petah Tikva affiliated to the Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

3. Soroka Cancer Institute Soroka Medical Center affiliated to Ben‐Gurion University of the Negev Beer‐Sheva Israel

4. Statistical Consulting Unit Rabin Medical Center affiliated to the Sackler Faculty of Medicine Petah Tikva Israel

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13360

Reference27 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Cancer statistics, 2013

3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

5. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition;Journal of Clinical Medicine;2023-05-28

2. Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors;Cancers;2022-12-11

3. Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis;Frontiers in Oncology;2022-09-06

4. Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2021-12